Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer

In a placebo-controlled randomised study of the platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate and docetaxel in metastatic prostate cancer with bone metastases (n=116), no significant differences in progression-free and overall survival were observed. To evaluate pharmac...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Mathew, P, Thall, P F, Wen, S, Bucana, C, Jones, D, Horne, E, Oh, W K, Morris, M J, Lee, Y-C, Logothetis, C J, Lin, S-H, Fidler, I J
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2008
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2579696/
https://ncbi.nlm.nih.gov/pubmed/18841158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604706
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki